-
Product Insights
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drugs In Development, 2023’, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Reflux Esophagitis (Gastroesophageal Reflux Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Reflux Esophagitis (Gastroesophageal Reflux Disease) Clinical Trials Market Report Overview The Reflux Esophagitis (Gastroesophageal Reflux Disease) clinical trial market research report provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) clinical trials scenario. This report provides top-line data relating to the clinical trials on Reflux Esophagitis and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7),...
-
Sector Analysis
Reflux Esophagitis (Gastroesophageal Reflux Disease) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Reflux Esophagitis (Gastroesophageal Reflux Disease) Marketed and Pipeline Drugs Report Overview Gastroesophageal Reflux Disease marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for reflux esophagitis (RE)/ gastroesophageal reflux disease (GERD). Gastroesophageal Reflux Disease Marketed Drugs Report Overview Key Mechanisms of Action · Enzyme Inhibitor · Receptor Agonist · Receptor Antagonist...